,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1332,1,1,,49698401,3948,Active,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
1,2240,1,1,,85788434,3948,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
2,2241,1,1,,85788434,3948,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
3,2275,1,1,,85788434,3948,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
4,2313,1,1,,85788434,3948,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
5,2322,1,1,,85788434,3948,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
6,2330,1,1,,85788434,3948,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
7,2660,1,1,,90340951,3948,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
8,2666,1,1,,90340951,3948,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
9,2667,1,1,,90340951,3948,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
10,2668,1,1,,90340951,3948,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
11,17991,3,3,,103178831,3948,Unspecified,,,,,Bioavailability,Other,12873497.0,
12,52945,6,2,,103178831,3948,Unspecified,,,,,In vitro antibacterial activity against gram-negative Citrobacter freundii,Other,14698166.0,
13,57388,7,4,,103178831,3948,Unspecified,,,,,Minimum inhibitory concentration against Escherichia coli DNA-gyrase in supercoiling assay,Other,1848296.0,
14,63898,7,2,,103178831,3948,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae MA2646",Other,1848296.0,
15,64251,7,2,,103178831,3948,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Escherichia coli vogel",Other,1848296.0,
16,67545,8,1,,103178831,3948,Unspecified,,,,,Activity against Enterobacter aerogenes,Other,12873497.0,
17,67922,3,3,,103178831,3948,Unspecified,,,,,Antibacterial activity evaluated against Enterococcus faecalis,Other,15163198.0,
18,69597,3,3,,103178831,3948,Unspecified,,,,,Antibacterial activity was evaluated against Escherichia coli,Other,15163198.0,
19,74723,4,3,,103178831,3948,Unspecified,,,,,MIC ratio measured as the mean MICs of gram-negative bacteria,Other,1848296.0,
20,74734,4,3,,103178831,3948,Unspecified,,,,,MIC ratio measured as the mean MICs of gram-positive bacteria,Other,1848296.0,
21,94001,7,2,,103178831,3948,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Klebsiella pneumoniae MGH-2",Other,1848296.0,
22,96403,6,2,,103178831,3948,Unspecified,,,,,In vitro antibacterial activity against gram-negative Klebsiella pneumoniae,Other,14698166.0,
23,135327,6,1,,103178831,3948,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
24,151052,7,2,,103178831,3948,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Pseudomonas aeruginosa UI-18",Other,1848296.0,
25,151374,7,2,,103178831,3948,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Providencia rettgeri. M1771",Other,1848296.0,
26,164231,3,3,,103178831,3948,Unspecified,,,,,Antibacterial activity was evaluated against Pseudomonas aeruginosa,Other,15163198.0,
27,197877,7,2,,103178831,3948,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Staphylococcus aureus H228",Other,1848296.0,
28,198021,7,2,,103178831,3948,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Streptococcus faecalis MGH-2",Other,1848296.0,
29,198176,7,2,,103178831,3948,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Streptococcus pneumoniae SV-1",Other,1848296.0,
30,198317,7,2,,103178831,3948,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Streptococcus pyogenes C203",Other,1848296.0,
31,200234,6,2,,103178831,3948,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Staphylococcus aureus UC76",Other,1848296.0,
32,203042,6,2,,103178831,3948,Unspecified,,,,,In vitro antibacterial activity against gram-negative Shigella boydii,Other,14698166.0,
33,205745,6,2,,103178831,3948,Unspecified,,,,,In vitro antibacterial activity against gram-positive Staphylococcus epidermidis,Other,14698166.0,
34,206600,6,2,,103178831,3948,Unspecified,,,,,In vitro antibacterial activity against gram-positive Staphylococcus aureus,Other,14698166.0,
35,206728,3,3,,103178831,3948,Unspecified,,,,,Antibacterial activity was evaluated against Staphylococcus aureus,Other,15163198.0,
36,210380,6,2,,103178831,3948,Unspecified,,,,,In vitro antibacterial activity against gram-positive Streptococcus pneumoniae,Other,14698166.0,
37,303474,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in UV light irradiated Swiss Albino mouse assessed as ear thickness at 140 mg/kg, po",Other,17960928.0,
38,303475,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss Albino mouse assessed as ear thickness at 140 mg/kg, po after 4 hrs of irradiation",Other,17960928.0,
39,303476,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss Albino mouse assessed as ear thickness at 140 mg/kg, po after 24 hrs of irradiation",Other,17960928.0,
40,303477,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss Albino mouse assessed as ear thickness at 140 mg/kg, po after 48 hrs of irradiation",Other,17960928.0,
41,303478,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss Albino mouse assessed as ear thickness at 140 mg/kg, po after 72 hrs of irradiation",Other,17960928.0,
42,303479,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss Albino mouse assessed as ear thickness at 140 mg/kg, po after 96 hrs of irradiation",Other,17960928.0,
43,303480,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in UV light irradiated Swiss Albino mouse assessed ear erythema at 140 mg/kg, po",Other,17960928.0,
44,303481,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss Albino mouse assessed as ear erythema at 140 mg/kg, po after 4 hrs of irradiation",Other,17960928.0,
45,303482,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss Albino mouse assessed as ear erythema at 140 mg/kg, po after 24 hrs of irradiation",Other,17960928.0,
46,303483,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss Albino mouse assessed as ear erythema at 140 mg/kg, po after 48 hrs of irradiation",Other,17960928.0,
47,303484,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss Albino mouse assessed as ear erythema at 140 mg/kg, po after 72 hrs of irradiation",Other,17960928.0,
48,303485,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss Albino mouse assessed as ear erythema at 140 mg/kg, po after 96 hrs of irradiation",Other,17960928.0,
49,307118,6,2,,103178831,3948,Inconclusive,,,,EC50,Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral-induced cytopathicity,Confirmatory,17376679.0,
50,307119,6,2,,103178831,3948,Inconclusive,,,,CC50,Cytotoxicity against CEM cells after 5 days by MTT method,Confirmatory,17376679.0,
51,307121,6,2,,103178831,3948,Inconclusive,,,,IC50,Inhibition of HIV1 recombinant integrase 3'-processing activity,Confirmatory,17376679.0,
52,307122,6,2,,103178831,3948,Inconclusive,,,,IC50,Inhibition of HIV1 recombinant integrase strand transfer activity,Confirmatory,17376679.0,
53,307123,6,2,,103178831,3948,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis by agar dilution method,Other,17376679.0,
54,316454,3,3,,103178831,3948,Unspecified,,,,,Phototoxic effect in mouse assessed as ear thickness at 140 mg/kg administered before UV light exposure relative to control,Other,18068979.0,
55,316455,3,3,,103178831,3948,Unspecified,,,,,"Phototoxic effect in UV light irradiated mouse assessed as ear thickness at 140 mg/kg, after 4 hrs relative to control",Other,18068979.0,
56,316456,3,3,,103178831,3948,Unspecified,,,,,"Phototoxic effect in UV light irradiated mouse assessed as ear thickness at 140 mg/kg, after 24 hrs relative to control",Other,18068979.0,
57,316457,3,3,,103178831,3948,Unspecified,,,,,"Phototoxic effect in UV light irradiated mouse assessed as ear thickness at 140 mg/kg, after 48 hrs relative to control",Other,18068979.0,
58,316458,3,3,,103178831,3948,Unspecified,,,,,"Phototoxic effect in UV light irradiated mouse assessed as ear thickness at 140 mg/kg, after 72 hrs relative to control",Other,18068979.0,
59,316459,3,3,,103178831,3948,Unspecified,,,,,"Phototoxic effect in UV light irradiated mouse assessed as ear thickness at 140 mg/kg, after 96 hrs relative to control",Other,18068979.0,
60,316460,3,3,,103178831,3948,Unspecified,,,,,Phototoxic effect in mouse assessed as number of mouse bearing erythema at 140 mg/kg administered before UV light exposure relative to control,Other,18068979.0,
61,316461,3,3,,103178831,3948,Unspecified,,,,,"Phototoxic effect in UV light irradiated mouse assessed as number of mouse bearing erythema at 140 mg/kg, after 4 hrs relative to control",Other,18068979.0,
62,316462,3,3,,103178831,3948,Unspecified,,,,,"Phototoxic effect in UV light irradiated mouse assessed as number of mouse bearing erythema at 140 mg/kg, after 24 hrs relative to control",Other,18068979.0,
63,316463,3,3,,103178831,3948,Unspecified,,,,,"Phototoxic effect in UV light irradiated mouse assessed as number of mouse bearing erythema at 140 mg/kg, after 48 hrs relative to control",Other,18068979.0,
64,316464,3,3,,103178831,3948,Unspecified,,,,,"Phototoxic effect in UV light irradiated mouse assessed as number of mouse bearing erythema at 140 mg/kg, after 72 hrs relative to control",Other,18068979.0,
65,316465,3,3,,103178831,3948,Unspecified,,,,,"Phototoxic effect in UV light irradiated mouse assessed as number of mouse bearing erythema at 140 mg/kg, after 96 hrs relative to control",Other,18068979.0,
66,318929,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 4 hrs of irradiation",Other,18304818.0,
67,318930,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 24 hrs of irradiation",Other,18304818.0,
68,318931,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 48 hrs of irradiation",Other,18304818.0,
69,318932,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 72 hrs of irradiation",Other,18304818.0,
70,318933,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 96 hrs of irradiation",Other,18304818.0,
71,318934,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 4 hrs of irradiation",Other,18304818.0,
72,318935,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 24 hrs of irradiation",Other,18304818.0,
73,318936,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 48 hrs of irradiation",Other,18304818.0,
74,318937,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 48 hrs of irradiation",Other,18304818.0,
75,318938,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 96 hrs of irradiation",Other,18304818.0,
76,325860,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 4 hrs of irradiation",Other,18078756.0,
77,325861,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 24 hrs of irradiation",Other,18078756.0,
78,325862,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 48 hrs of irradiation",Other,18078756.0,
79,325863,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 72 hrs of irradiation",Other,18078756.0,
80,325864,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po after 96 hrs of irradiation",Other,18078756.0,
81,325865,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 4 hrs of irradiation",Other,18078756.0,
82,325866,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 24 hrs of irradiation",Other,18078756.0,
83,325867,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 48 hrs of irradiation",Other,18078756.0,
84,325868,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 48 hrs of irradiation",Other,18078756.0,
85,325869,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as erythema incidence at 140 mg/kg, po after 96 hrs of irradiation",Other,18078756.0,
86,349880,8,1,,103178831,3948,Unspecified,,,,,Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA,Other,19374444.0,
87,367084,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus after 24 hrs by agar dilution method,Other,19095449.0,
88,367085,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae after 24 hrs by agar dilution method,Other,19095449.0,
89,367086,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Staphylococcus albus after 24 hrs by agar dilution method,Other,19095449.0,
90,367087,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Staphylococcus epidermidis after 24 hrs by agar dilution method,Other,19095449.0,
91,367088,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis after 24 hrs by agar dilution method,Other,19095449.0,
92,367089,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against gamma-streptococcus after 24 hrs by agar dilution method,Other,19095449.0,
93,367090,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Escherichia coli after 24 hrs by agar dilution method,Other,19095449.0,
94,367363,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Shigella sonnei after 24 hrs by agar dilution method,Other,19095449.0,
95,368418,6,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Escherichia coli C316 pHPA containing mutated GyrA gene by agar dilution method,Other,17548499.0,
96,368419,6,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Escherichia coli KAM32 expressing deltaacrB ydhE hsd gene by agar dilution method,Other,17548499.0,
97,368420,6,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Escherichia coli KAM32 pHPA containing mutated GyrA gene by agar dilution method,Other,17548499.0,
98,368421,6,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Escherichia coli KAM32 pSTV28 containing chloramphenicol-resistant vector by agar dilution method,Other,17548499.0,
99,368422,6,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Escherichia coli KAM32 pSTVqepA containing qepA gene ligated to pSTV28 plasmid by agar dilution method,Other,17548499.0,
100,368423,6,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Escherichia coli KAM32 pSTVdeltaqepA containing disrupted qepA gene by agar dilution method,Other,17548499.0,
101,368424,3,3,,103178831,3948,Unspecified,,,,,Ratio of MIC for Escherichia coli KAM32 pSTVqepA mutant to MIC for Escherichia coli KAM32 pSTV28 mutant,Other,17548499.0,
102,370633,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Shigella boydii after 24 hrs by agar dilution method,Other,19095449.0,
103,370634,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Shigella flexneri after 24 hrs by agar dilution method,Other,19095449.0,
104,370635,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Proteus mirabilis after 24 hrs by agar dilution method,Other,19095449.0,
105,370636,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Proteus vulgaris after 24 hrs by agar dilution method,Other,19095449.0,
106,370637,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by agar dilution method,Other,19095449.0,
107,370638,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Morganella morganii after 24 hrs by agar dilution method,Other,19095449.0,
108,370639,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae after 24 hrs by agar dilution method,Other,19095449.0,
109,370640,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Salmonella enteritidis after 24 hrs by agar dilution method,Other,19095449.0,
110,370641,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Salmonella Typhimurium after 24 hrs by agar dilution method,Other,19095449.0,
111,370642,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Citrobacter freundii after 24 hrs by agar dilution method,Other,19095449.0,
112,370643,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Aeromonas hydrophila after 24 hrs by agar dilution method,Other,19095449.0,
113,370644,6,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Serratia marcescens after 24 hrs by agar dilution method,Other,19095449.0,
114,394293,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse exposed to 18 J/cm'2 UV light irradiation assessed as ear thickness at 140 mg/kg, po",Other,18502542.0,
115,394294,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as ear thickness at 140 mg/kg, po measured after 4 hrs of 18 J/cm'2 UV light irradiation",Other,18502542.0,
116,394295,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as ear thickness at 140 mg/kg, po after 24 hrs",Other,18502542.0,
117,394296,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as ear thickness at 140 mg/kg, po after 48 hrs",Other,18502542.0,
118,394297,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as ear thickness at 140 mg/kg, po after 72 hrs",Other,18502542.0,
119,394298,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as ear thickness at 140 mg/kg, po after 96 hrs",Other,18502542.0,
120,394299,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as erythema at 140 mg/kg, po",Other,18502542.0,
121,394300,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse assessed as erythema at 140 mg/kg, po after 4 hrs of 18 J/cm'2 UV light irradiation",Other,18502542.0,
122,394301,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as erythema at 140 mg/kg, po after 24 hrs",Other,18502542.0,
123,394302,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as erythema at 140 mg/kg, po after 48 hrs",Other,18502542.0,
124,394303,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as erythema at 140 mg/kg, po after 72 hrs",Other,18502542.0,
125,394304,3,3,,103178831,3948,Unspecified,,,,,"Phototoxicity in Swiss albino mouse exposed to 4 hrs of 18 J/cm'2 UV light irradiation assessed as erythema at 140 mg/kg, po after 96 hrs",Other,18502542.0,
126,395097,6,2,,103178831,3948,Unspecified,,,197.0,IC50,Antitrypanosomal activity against wild type Trypanosoma brucei brucei s427 after 48 hrs by alamar blue assay,Confirmatory,19250832.0,
127,427196,8,1,,103178831,3948,Unspecified,,,,,Membrane permeability by PAMPA-BBB assay,Other,19663388.0,
128,427197,8,1,,103178831,3948,Unspecified,,,,,Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay,Other,19663388.0,
129,427198,8,1,,103178831,3948,Unspecified,,,,,Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay,Other,19663388.0,
130,434959,1,1,,85788434,3948,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
131,436988,5,2,,103178831,3948,Unspecified,,,410.0,IC50,Inhibition of human HeLa cell proliferation,Confirmatory,19595598.0,
132,436997,5,2,,103178831,3948,Unspecified,,,483.0,IC50,Inhibition of mouse NIH/3T3 cell proliferation by MTT assay,Confirmatory,19595598.0,
133,445445,7,1,,103178831,3948,Unspecified,,,,,Permeability at pH 6.5 by PAMPA method,Other,19947605.0,
134,445446,3,4,,103178831,3948,Unspecified,,,,,Oral bioavailability in human,Other,19947605.0,
135,463106,1,2,,90340951,3948,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
136,467611,3,6,,103178831,3948,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
137,467612,3,6,,103178831,3948,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
138,467613,5,3,,103178831,3948,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
139,469403,5,1,,103178831,3948,Unspecified,,,,,Permeability across PAMPA membrane,Other,19856923.0,
140,485295,1,2,,90340951,3948,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
141,485297,1,1,,90340951,3948,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
142,485298,1,1,,90340951,3948,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
143,485313,1,2,,90340951,3948,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
144,485342,1,2,,90340951,3948,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
145,485345,1,2,,90340951,3948,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
146,485366,1,2,,90340951,3948,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
147,485368,1,2,,90340951,3948,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
148,488772,1,1,,90340951,3948,Inactive,8659577.0,58819.0,21.1923,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
149,488773,1,2,,90340951,3948,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
150,488816,1,1,,90340951,3948,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
151,488837,1,1,,90340951,3948,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
152,488949,1,2,,90340951,3948,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
153,488953,1,1,,90340951,3948,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
154,488978,1,1,,90340951,3948,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
155,488981,1,1,,90340951,3948,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
156,488982,1,1,,90340951,3948,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
157,488983,1,1,,90340951,3948,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
158,493106,1,1,,90340951,3948,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
159,493107,1,1,,90340951,3948,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
160,493153,1,1,,90340951,3948,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
161,493153,1,1,,90340951,3948,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
162,493164,1,2,,90340951,3948,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
163,493164,1,2,,90340951,3948,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
164,493164,1,2,,90340951,3948,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
165,504327,1,1,,90340951,3948,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
166,504332,1,1,,90340951,3948,Active,168985070.0,,11.2202,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
167,504536,1,1,,90340951,3948,Inconclusive,5453898.0,5300.0,10.690999999999999,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
168,504547,1,1,,90340951,3948,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
169,504548,1,2,,90340951,3948,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
170,504810,1,2,,90340951,3948,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
171,504812,1,2,,90340951,3948,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
172,504836,1,2,,90340951,3948,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
173,504845,1,1,,90340951,3948,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
174,504847,1,1,,90340951,3948,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
175,504865,1,1,,90340951,3948,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
176,515780,5,1,,103178831,3948,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
177,540256,1,2,,90340951,3948,Inconclusive,,,23.0999,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
178,540276,1,2,,50111115,3948,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
179,540276,1,2,,50122922,3948,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
180,540276,1,2,,90340951,3948,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
181,562240,5,2,,103178831,3948,Active,,,4.33,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry,Confirmatory,19786608.0,
182,562241,5,2,,103178831,3948,Active,,,4.88,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry,Confirmatory,19786608.0,
183,562242,5,2,,103178831,3948,Active,,,1.44,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry,Confirmatory,19786608.0,
184,562243,5,2,,103178831,3948,Active,,,4.33,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay,Confirmatory,19786608.0,
185,562244,5,2,,103178831,3948,Active,,,4.88,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay,Confirmatory,19786608.0,
186,562245,5,2,,103178831,3948,Active,,,1.44,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay,Confirmatory,19786608.0,
187,563500,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Serratia marcescens ATCC 13880 by broth dilution method,Other,19752278.0,
188,563501,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens 01 by broth dilution method,Other,19752278.0,
189,563502,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 71 by broth dilution method,Other,19752278.0,
190,563503,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 79 by broth dilution method,Other,19752278.0,
191,563504,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Serratia marcescens ATCC 13880 harboring plasmid STV29 by broth dilution method,Other,19752278.0,
192,563505,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens 01 harboring plasmid STV29 by broth dilution method,Other,19752278.0,
193,563506,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 71 harboring plasmid STV29 by broth dilution method,Other,19752278.0,
194,563507,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 71 harboring plasmid STV29 expressing hasF gene by broth dilution method,Other,19752278.0,
195,563508,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 79 harboring plasmid STV29 by broth dilution method,Other,19752278.0,
196,563509,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 79 harboring plasmid STV29 expressing hasF gene by broth dilution method,Other,19752278.0,
197,563510,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens HMS011 by broth dilution method,Other,19752278.0,
198,563511,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens HMS011 harboring plasmid STV28 expressing sdeB gene by broth dilution method,Other,19752278.0,
199,563512,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens 011 by broth dilution method,Other,19752278.0,
200,563513,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens 011 harboring plasmid STV28 expressing sdeB gene by broth dilution method,Other,19752278.0,
201,572147,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomeganorM plasmid containing Neisseria gonorrhoeae multidrug efflux pump NorM after 18 to 24 hrs by two fold dilution method,Other,18591276.0,
202,572150,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBAD plasmid after 18 to 24 hrs by two fold dilution method,Other,18591276.0,
203,572151,5,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomegaydhE plasmid containing Escherichia coli multidrug efflux pump YdhE after 18 to 24 hrs by two fold dilution method,Other,18591276.0,
204,576612,7,5,,103178831,3948,Unspecified,7531135.0,3757.0,2398.83,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
205,588214,2,3,,103178831,3948,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
206,588215,2,3,,103178831,3948,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
207,588216,2,3,,103178831,3948,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
208,588217,2,3,,103178831,3948,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
209,588218,2,3,,103178831,3948,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
210,588219,2,3,,103178831,3948,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
211,588349,1,1,,90340951,3948,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
212,588378,1,1,,90340951,3948,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
213,588453,1,1,,90340951,3948,Inactive,8659577.0,58819.0,22.3872,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
214,588456,1,1,,90340951,3948,Inactive,8659577.0,58819.0,31.6228,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
215,588579,1,1,,90340951,3948,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
216,588795,1,1,,90340951,3948,Inconclusive,4758356.0,2237.0,18.8876,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
217,602332,1,1,,90340951,3948,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
218,624101,1,2,,85788434,3948,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
219,624146,1,1,,90340951,3948,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
220,624147,1,1,,90340951,3948,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
221,624148,1,2,,90340951,3948,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
222,624149,1,1,,90340951,3948,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
223,624156,1,1,,85788434,3948,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
224,624349,1,2,,92309292,3948,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
225,624455,1,1,,90340951,3948,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
226,625144,5,5,,103178831,3948,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
227,625145,4,7,,103178831,3948,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
228,625146,5,5,,103178831,3948,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
229,625147,4,7,,103178831,3948,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
230,625148,4,7,,103178831,3948,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
231,625149,4,7,,103178831,3948,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
232,625150,5,5,,103178831,3948,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
233,625151,4,7,,103178831,3948,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
234,625152,4,7,,103178831,3948,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
235,625153,4,7,,103178831,3948,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
236,625154,4,7,,103178831,3948,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
237,625155,4,7,,103178831,3948,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
238,625156,1,9,,103178831,3948,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
239,625157,6,2,,103178831,3948,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
240,625158,3,4,,103178831,3948,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
241,625159,5,5,,103178831,3948,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
242,625160,1,9,,103178831,3948,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
243,625161,4,7,,103178831,3948,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
244,625162,4,7,,103178831,3948,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
245,625163,4,7,,103178831,3948,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
246,625164,1,6,,103178831,3948,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
247,625165,3,4,,103178831,3948,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
248,625166,3,4,,103178831,3948,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
249,625167,5,5,,103178831,3948,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
250,625168,4,7,,103178831,3948,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
251,625169,1,6,,103178831,3948,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
252,625170,3,4,,103178831,3948,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
253,625171,4,7,,103178831,3948,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
254,625172,4,7,,103178831,3948,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
255,625173,5,5,,103178831,3948,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
256,625174,5,5,,103178831,3948,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
257,625175,5,5,,103178831,3948,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
258,625176,1,9,,103178831,3948,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
259,625177,5,5,,103178831,3948,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
260,625178,5,5,,103178831,3948,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
261,625179,1,9,,103178831,3948,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
262,625180,5,5,,103178831,3948,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
263,625181,5,5,,103178831,3948,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
264,625182,5,5,,103178831,3948,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
265,625183,5,5,,103178831,3948,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
266,625184,5,5,,103178831,3948,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
267,625185,5,5,,103178831,3948,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
268,625186,5,5,,103178831,3948,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
269,625187,5,5,,103178831,3948,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
270,625188,1,9,,103178831,3948,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
271,625189,1,7,,103178831,3948,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
272,625190,4,5,,103178831,3948,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
273,625191,4,7,,103178831,3948,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
274,625192,4,7,,103178831,3948,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
275,625193,5,5,,103178831,3948,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
276,625194,4,7,,103178831,3948,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
277,625195,4,7,,103178831,3948,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
278,625196,5,6,,103178831,3948,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
279,625197,3,4,,103178831,3948,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
280,625198,4,7,,103178831,3948,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
281,625199,4,7,,103178831,3948,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
282,625200,4,7,,103178831,3948,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
283,625201,4,7,,103178831,3948,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
284,625202,4,7,,103178831,3948,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
285,625203,4,7,,103178831,3948,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
286,625204,4,7,,103178831,3948,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
287,625205,4,7,,103178831,3948,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
288,625206,4,7,,103178831,3948,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
289,625207,4,7,,103178831,3948,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
290,625208,5,5,,103178831,3948,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
291,625209,4,7,,103178831,3948,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
292,625210,3,4,,103178831,3948,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
293,625211,1,6,,103178831,3948,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
294,625212,3,4,,103178831,3948,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
295,625213,4,7,,103178831,3948,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
296,625214,1,9,,103178831,3948,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
297,625215,3,4,,103178831,3948,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
298,625216,3,4,,103178831,3948,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
299,625217,4,7,,103178831,3948,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
300,625218,4,7,,103178831,3948,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
301,625219,3,4,,103178831,3948,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
302,625220,4,7,,103178831,3948,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
303,625221,4,7,,103178831,3948,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
304,625222,4,7,,103178831,3948,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
305,625223,4,7,,103178831,3948,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
306,625224,3,4,,103178831,3948,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
307,625225,3,4,,103178831,3948,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
308,625226,4,7,,103178831,3948,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
309,625227,4,7,,103178831,3948,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
310,625228,4,7,,103178831,3948,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
311,625229,5,5,,103178831,3948,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
312,625230,1,6,,103178831,3948,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
313,625231,4,7,,103178831,3948,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
314,625232,1,9,,103178831,3948,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
315,625233,4,7,,103178831,3948,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
316,625234,3,4,,103178831,3948,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
317,625235,4,7,,103178831,3948,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
318,625236,5,5,,103178831,3948,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
319,625237,4,7,,103178831,3948,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
320,625238,4,7,,103178831,3948,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
321,625239,4,7,,103178831,3948,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
322,625240,1,9,,103178831,3948,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
323,625241,4,7,,103178831,3948,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
324,625242,4,7,,103178831,3948,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
325,625243,5,5,,103178831,3948,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
326,625244,5,5,,103178831,3948,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
327,625245,5,5,,103178831,3948,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
328,625246,1,9,,103178831,3948,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
329,625247,5,5,,103178831,3948,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
330,625248,5,5,,103178831,3948,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
331,625249,5,5,,103178831,3948,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
332,625250,5,5,,103178831,3948,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
333,625251,5,5,,103178831,3948,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
334,625252,4,7,,103178831,3948,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
335,625253,4,7,,103178831,3948,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
336,625254,4,7,,103178831,3948,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
337,625255,4,7,,103178831,3948,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
338,625256,4,7,,103178831,3948,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
339,625257,4,7,,103178831,3948,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
340,625258,4,7,,103178831,3948,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
341,625259,4,7,,103178831,3948,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
342,625260,3,4,,103178831,3948,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
343,625261,3,4,,103178831,3948,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
344,625262,3,4,,103178831,3948,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
345,625263,4,7,,103178831,3948,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
346,625264,3,4,,103178831,3948,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
347,625265,1,6,,103178831,3948,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
348,625266,3,4,,103178831,3948,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
349,625267,3,4,,103178831,3948,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
350,625268,4,2,,103178831,3948,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
351,625268,4,2,,103178831,3948,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
352,625268,4,2,,103178831,3948,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
353,625268,4,2,,103178831,3948,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
354,625269,4,7,,103178831,3948,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
355,625270,4,7,,103178831,3948,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
356,625271,5,5,,103178831,3948,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
357,625272,3,4,,103178831,3948,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
358,625273,4,6,,103178831,3948,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
359,625274,1,6,,103178831,3948,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
360,625275,3,4,,103178831,3948,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
361,625279,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
362,625280,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
363,625281,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
364,625282,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
365,625283,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
366,625284,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
367,625285,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
368,625286,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
369,625287,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
370,625288,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
371,625289,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
372,625290,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
373,625291,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
374,625292,1,3,,103178831,3948,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
375,639368,3,1,,103178831,3948,Unspecified,,,,,Permeability of the compound by PAMPA assay,Other,21420206.0,
376,651635,1,3,,90340951,3948,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
377,651828,1,2,,92309292,3948,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
378,652106,1,1,,90340951,3948,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
379,679038,1,8,,103178831,3948,Unspecified,3219824.0,25303.0,,,"TP_TRANSPORTER: inhibition of DNP-SG uptake (DNP-SG: 1 uM, LFLX: 10000uM) in bile canalicular membrane vesicles from SD rat",Other,9495864.0,
380,679039,1,8,,103178831,3948,Unspecified,3219824.0,25303.0,,,"TP_TRANSPORTER: inhibition of DNP-SG uptake (DNP-SG: 1 uM, LFLX: 10000uM) in bile canalicular membrane vesicles from EHBR rat",Other,9495864.0,
381,682307,1,7,,103178831,3948,Unspecified,8928257.0,6584.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, LFLX: 500 uM) in OCTN2-expressing HEK293 cells",Other,10525100.0,
382,686977,2,1,,49698401,3948,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
383,718840,2,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa CMCC 10104 after 24 hrs by agar dilution method,Other,23102889.0,
384,718841,2,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Escherichia coli CMCC 44103 after 24 hrs by agar dilution method,Other,23102889.0,
385,718842,2,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus CMCC 26003 after 24 hrs by agar dilution method,Other,23102889.0,
386,720538,1,2,,90340951,3948,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
387,720559,1,2,,90340951,3948,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
388,720572,1,2,,90340951,3948,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
389,720573,1,2,,90340951,3948,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
390,720641,1,2,,92309292,3948,Active,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
391,720717,1,3,,92309292,3948,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
392,743205,1,1,,90340951,3948,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
393,743205,1,1,,90340951,3948,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
394,743206,1,1,,90340951,3948,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
395,743206,1,1,,90340951,3948,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
396,743207,1,1,,90340951,3948,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
397,743207,1,1,,90340951,3948,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
398,743244,1,1,,90340951,3948,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
399,743344,1,1,,174007186,3948,Inactive,,,16.7744,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
400,743345,1,1,,174007186,3948,Inactive,,,0.006,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
401,743346,1,1,,174007186,3948,Inactive,,,10.5839,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
402,743347,1,1,,174007186,3948,Inactive,,,13.3244,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
403,781330,1,2,,103178831,3948,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by potentiometric titration,Other,24249037.0,
404,939306,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020423,Other,,
405,939307,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020423,Other,,
406,939308,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020423,Other,,
407,939309,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020423,Other,,
408,939937,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020423,Other,,
409,939938,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020423,Other,,
410,939939,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020423,Other,,
411,939940,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020423,Other,,
412,939941,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020423,Other,,
413,939942,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020423,Other,,
414,939943,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020423,Other,,
415,939944,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020423,Other,,
416,939945,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020423,Other,,
417,939946,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020423,Other,,
418,939947,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020423,Other,,
419,939948,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020423,Other,,
420,939949,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020423,Other,,
421,939950,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020423,Other,,
422,939951,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020423,Other,,
423,939952,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020423,Other,,
424,939953,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020423,Other,,
425,939954,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020423,Other,,
426,939955,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020423,Other,,
427,939956,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020423,Other,,
428,939957,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020423,Other,,
429,939958,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020423,Other,,
430,956244,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020423,Other,,
431,956245,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020423,Other,,
432,956246,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020423,Other,,
433,956247,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020423,Other,,
434,956248,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020423,Other,,
435,956249,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020423,Other,,
436,956250,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020423,Other,,
437,956251,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020423,Other,,
438,956252,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020423,Other,,
439,956253,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020423,Other,,
440,958129,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020423,Other,,
441,958130,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020423,Other,,
442,958131,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020423,Other,,
443,958132,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020423,Other,,
444,958133,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020423,Other,,
445,958134,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020423,Other,,
446,958135,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020423,Other,,
447,958136,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020423,Other,,
448,958711,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020423,Other,,
449,958712,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020423,Other,,
450,958713,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020423,Other,,
451,958714,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020423,Other,,
452,958715,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020423,Other,,
453,958716,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020423,Other,,
454,958717,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020423,Other,,
455,958718,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020423,Other,,
456,958719,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020423,Other,,
457,958720,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020423,Other,,
458,997949,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: R020423,Other,,
459,997950,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R020423",Other,,
460,997951,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: R020423",Other,,
461,998529,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: R020423",Other,,
462,998530,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: R020423",Other,,
463,998531,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: R020423",Other,,
464,998532,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R020423",Other,,
465,998533,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: R020423",Other,,
466,998534,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: R020423",Other,,
467,998535,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: R020423",Other,,
468,998536,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: R020423",Other,,
469,998537,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: R020423,Other,,
470,998538,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: R020423",Other,,
471,998539,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: R020423,Other,,
472,998540,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: R020423",Other,,
473,998541,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: R020423",Other,,
474,998542,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: R020423",Other,,
475,998543,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: R020423",Other,,
476,998544,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: R020423",Other,,
477,998545,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: R020423",Other,,
478,998546,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: R020423",Other,,
479,998547,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: R020423",Other,,
480,1000410,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: R020423",Other,,
481,1000411,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020423",Other,,
482,1000412,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R020423",Other,,
483,1000413,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: R020423",Other,,
484,1000414,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: R020423,Other,,
485,1000415,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: R020423",Other,,
486,1000416,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: R020423",Other,,
487,1000417,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: R020423",Other,,
488,1000418,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: R020423",Other,,
489,1000419,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: R020423",Other,,
490,1000420,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: R020423",Other,,
491,1000421,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: R020423",Other,,
492,1000422,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: R020423",Other,,
493,1000423,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: R020423",Other,,
494,1000424,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: R020423",Other,,
495,1000425,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: R020423",Other,,
496,1000426,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: R020423",Other,,
497,1001006,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: R020423",Other,,
498,1001007,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: R020423,Other,,
499,1001008,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: R020423",Other,,
500,1001009,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: R020423",Other,,
501,1001010,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: R020423",Other,,
502,1001011,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: R020423",Other,,
503,1001012,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: R020423",Other,,
504,1001013,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: R020423",Other,,
505,1001014,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: R020423",Other,,
506,1001015,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: R020423",Other,,
507,1001016,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020423",Other,,
508,1001017,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: R020423",Other,,
509,1001018,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: R020423",Other,,
510,1001019,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: R020423",Other,,
511,1001020,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: R020423,Other,,
512,1001021,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020423",Other,,
513,1001022,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: R020423",Other,,
514,1001023,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: R020423",Other,,
515,1001024,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: R020423",Other,,
516,1001025,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: R020423",Other,,
517,1001026,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: R020423",Other,,
518,1001027,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: R020423",Other,,
519,1001028,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: R020423",Other,,
520,1002894,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: R020423",Other,,
521,1002895,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: R020423",Other,,
522,1002896,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: R020423",Other,,
523,1002897,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: R020423",Other,,
524,1002898,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: R020423",Other,,
525,1002899,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: R020423",Other,,
526,1002900,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020423",Other,,
527,1002901,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: R020423,Other,,
528,1002902,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: R020423",Other,,
529,1002903,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: R020423",Other,,
530,1002904,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: R020423",Other,,
531,1002905,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: R020423",Other,,
532,1003489,1,3,,103178831,3948,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: R020423,Other,,
533,1003490,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: R020423",Other,,
534,1003491,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: R020423",Other,,
535,1003492,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: R020423",Other,,
536,1003493,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: R020423",Other,,
537,1003494,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: R020423",Other,,
538,1003495,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: R020423",Other,,
539,1003496,1,3,,103178831,3948,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: R020423",Other,,
540,1056992,1,1,,103178831,3948,Unspecified,,,,,Permeability of the compound by PAMPA,Other,24128814.0,
541,1056993,1,1,,103178831,3948,Unspecified,,,,,Permeability of the compound at 100 mg/mL after 10 hrs by PAMPA,Other,24128814.0,
542,1071344,1,1,,103178831,3948,Unspecified,,,,,Permeability of the compound by BBB-PAMPA,Other,24389509.0,
543,1079931,1,1,,103178831,3948,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
544,1079932,1,1,,103178831,3948,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
545,1079933,1,1,,103178831,3948,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
546,1079934,1,1,,103178831,3948,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
547,1079935,1,1,,103178831,3948,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
548,1079936,1,1,,103178831,3948,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
549,1079937,1,1,,103178831,3948,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
550,1079938,1,1,,103178831,3948,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
551,1079939,1,1,,103178831,3948,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
552,1079940,1,1,,103178831,3948,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
553,1079941,1,1,,103178831,3948,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
554,1079942,1,1,,103178831,3948,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
555,1079943,1,1,,103178831,3948,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
556,1079944,1,1,,103178831,3948,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
557,1079945,1,1,,103178831,3948,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
558,1079946,1,1,,103178831,3948,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
559,1079947,1,1,,103178831,3948,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
560,1079948,1,1,,103178831,3948,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
561,1079949,1,1,,103178831,3948,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
562,1084881,1,2,,103178831,3948,Unspecified,,,,,"Antimycobacterial activity against rifampicin,amphiciline and kanamycin-resistant Mycobacterium smegmatis MDR-40 after 24 hr by two-fold serial micro broth dilution method",Other,,
563,1084882,1,2,,103178831,3948,Unspecified,,,,,"Antimycobacterial activity against rifampicin,tetracycline and chloramphenicol-resistant Mycobacterium smegmatis MDR-R after 24 hr by two-fold serial micro broth dilution method",Other,,
564,1084883,1,2,,103178831,3948,Unspecified,,,,,Antimycobacterial activity against quinolones and ciprofloxacin-resistant Mycobacterium smegmatis MDRQ after 24 hr by two-fold serial micro broth dilution method,Other,,
565,1084884,1,2,,103178831,3948,Unspecified,,,,,Antimycobacterial activity against lomofloxacin-resistant Mycobacterium smegmatis Lom R5 after 24 hr by two-fold serial micro broth dilution method,Other,,
566,1084885,1,2,,103178831,3948,Unspecified,,,,,"Antimycobacterial activity against ciprofloxacin,lomofloxacin and norflaxacin-resistant Mycobacterium smegmatis CSC-101 after 24 hr by two-fold serial micro broth dilution method",Other,,
567,1084886,1,2,,103178831,3948,Unspecified,,,,,Antimycobacterial activity against Mycobacterium smegmatis str. MC2 155 after 24 hr by two-fold serial micro broth dilution method,Other,,
568,1093543,1,2,,103178831,3948,Unspecified,,,,,Antibacterial activity against Escherichia coli NCTC 10418 infected in po dosed CF mouse compound administered 1 hr prior and 4 hr post infection,Other,,
569,1093546,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Vibrio cholerae 01 after 18 to 20 hr by agar dilution method,Other,,
570,1093547,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Bacillus megaterium after 18 to 20 hr by agar dilution method,Other,,
571,1093548,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Enterobacter after 18 to 20 hr by agar dilution method,Other,,
572,1093549,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Citrobacter freundii after 18 to 20 hr by agar dilution method,Other,,
573,1093550,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Salmonella enterica subsp. enterica serovar Enteritidis after 18 to 20 hr by agar dilution method,Other,,
574,1093551,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Salmonella enterica subsp. enterica serovar Typhi after 18 to 20 hr by agar dilution method,Other,,
575,1093552,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Salmonella enterica subsp. enterica serovar Paratyphi A after 18 to 20 hr by agar dilution method,Other,,
576,1093553,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Salmonella enterica subsp. enterica serovar Typhimurium after 18 to 20 hr by agar dilution method,Other,,
577,1093554,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Proteus mirabilis after 18 to 20 hr by agar dilution method,Other,,
578,1093555,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Proteus vulgaris after 18 to 20 hr by agar dilution method,Other,,
579,1093556,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Edwardsiella tarda after 18 to 20 hr by agar dilution method,Other,,
580,1093557,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Escherichia coli NCTC 10418 after 18 to 20 hr by agar dilution method,Other,,
581,1093558,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Vibrio parahaemolyticus after 18 to 20 hr by agar dilution method,Other,,
582,1093559,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Vibrio cholerae 0139 after 18 to 20 hr by agar dilution method,Other,,
583,1093560,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Vibrio fluvialis after 18 to 20 hr by agar dilution method,Other,,
584,1093561,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Vibrio mimicus after 18 to 20 hr by agar dilution method,Other,,
585,1093562,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa after 18 to 20 hr by agar dilution method,Other,,
586,1093563,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus after 18 to 20 hr by agar dilution method,Other,,
587,1093564,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Morganella morganii after 18 to 20 hr by agar dilution method,Other,,
588,1093565,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Shigella boydii after 18 to 20 hr by agar dilution method,Other,,
589,1093566,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Plesiomonas after 18 to 20 hr by agar dilution method,Other,,
590,1093567,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Shigella sonnei after 18 to 20 hr by agar dilution method,Other,,
591,1093568,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Klebsiella pneumoniae after 18 to 20 hr by agar dilution method,Other,,
592,1093569,1,2,,103178831,3948,Unspecified,,,,,Antimicrobial activity against Klebsiella pneumoniae subsp. ozaenae after 18 to 20 hr by agar dilution method,Other,,
593,1159386,1,2,,103178831,3948,Unspecified,,,,,ASTRAZENECA: Most basic pKa value (pKa B1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Bases: >= 2.,Other,,
594,1159387,1,2,,103178831,3948,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
595,1159399,1,2,,103178831,3948,Unspecified,,,,,ASTRAZENECA: Most acidic pKa value (pKa A1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Acids: <= 11.,Other,,
596,1159580,2,1,,268734865,3948,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
597,1159580,2,1,,273002854,3948,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
598,1159607,2,1,,312596106,3948,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
599,1161578,1,1,,103178831,3948,Unspecified,,,,,Permeability of the compound by PAMPA-BBB assay,Other,25156301.0,
600,1167550,1,1,,103178831,3948,Unspecified,,,,,Permeability of the compound in 70:30 PBS:EtOH by PAMPA-BBB assay,Other,25282266.0,
601,1173449,1,1,,103178831,3948,Unspecified,,,,,Effective permeability of the compound by PAMPA assay,Other,25454267.0,
602,1183278,1,1,,103178831,3948,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25016233.0,
603,1190185,1,1,,103178831,3948,Unspecified,,,,,Permeability of the compound after 16 hrs by PAMPA,Other,25542589.0,
604,1198140,1,1,,103178831,3948,Unspecified,,,,,Permeability of the compound in PBS and EtOH by PAMPA method,Other,25656088.0,
605,1224824,1,1,,174007186,3948,Inactive,,,23.485,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
606,1224825,1,1,,174007186,3948,Inactive,,,0.1663,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
607,1224857,2,1,,174007186,3948,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
608,1224859,2,1,,90340951,3948,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
609,1224859,2,1,,174007186,3948,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
610,1224863,1,1,,176484398,3948,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
611,1224863,1,1,,176485040,3948,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
612,1224863,1,1,,316919065,3948,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
613,1224905,2,1,,92309292,3948,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
614,1224905,2,1,,92309292,3948,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
615,1259252,1,1,,174007186,3948,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
616,1259253,1,1,,174007186,3948,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
617,1259255,1,1,,174007186,3948,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
618,1259256,1,1,,174007186,3948,Inactive,169655958.0,,0.7427,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
619,1259407,1,1,,363904255,3948,Inactive,,,,,CCRIS mutagenicity studies,Other,,
620,1259416,1,2,,340080139,3948,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
621,1259416,1,2,,375172115,3948,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
622,1259421,1,1,,340080139,3948,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
623,1259421,1,1,,375172115,3948,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
624,1259423,1,2,,354775904,3948,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
625,1259423,1,2,,354796211,3948,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
626,1259423,1,2,,354954966,3948,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
627,1259423,1,2,,354956006,3948,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
